Cargando…

Maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study

OBJECTIVE: To evaluate oxytocin use for augmentation of labour in relation to body mass index (BMI) on admission to the labour ward, focusing on cumulative oxytocin dose and maximum rate of oxytocin infusion during the first stage of labour. DESIGN: Prospective observational study. SETTING: Seven ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramö Isgren, Anna, Kjölhede, Preben, Carlhäll, Sara, Blomberg, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006853/
https://www.ncbi.nlm.nih.gov/pubmed/33771828
http://dx.doi.org/10.1136/bmjopen-2020-044754
_version_ 1783672381795991552
author Ramö Isgren, Anna
Kjölhede, Preben
Carlhäll, Sara
Blomberg, Marie
author_facet Ramö Isgren, Anna
Kjölhede, Preben
Carlhäll, Sara
Blomberg, Marie
author_sort Ramö Isgren, Anna
collection PubMed
description OBJECTIVE: To evaluate oxytocin use for augmentation of labour in relation to body mass index (BMI) on admission to the labour ward, focusing on cumulative oxytocin dose and maximum rate of oxytocin infusion during the first stage of labour. DESIGN: Prospective observational study. SETTING: Seven hospitals in Sweden. PARTICIPANTS: 1097 nulliparous women with singleton cephalic presentation pregnancy, ≥37 weeks of gestation, spontaneous onset of labour and treatment with oxytocin infusion for labour augmentation. The study population was classified into three BMI subgroups on admission to the labour ward: normal weight (18.5–24.9), overweight (25.0–29.9) and obese (≥30.0). The cumulative oxytocin dose was measured from the start of oxytocin infusion until the neonate was born. PRIMARY OUTCOME: Cumulative oxytocin dose. SECONDARY OUTCOME: Maximum rate of oxytocin infusion during the active phase of first stage of labour. RESULTS: The mean cumulative oxytocin dose increased in the BMI groups (normal weight 2278 mU, overweight 3108 mU and obese 4082 mU (p<0.0001)). However, when adjusted for the confounders (cervical dilatation when oxytocin infusion was started, fetal birth weight, epidural analgesia), the significant difference was no longer seen. The maximum oxytocin infusion rate during the first stage of labour differed significantly in the BMI groups when adjusted for the confounding factors individually but not when adjusted for all three factors simultaneously. In addition, the maximum oxytocin infusion rate was significantly higher in women with emergency caesarean section compared with women with vaginal delivery. CONCLUSIONS: Women with increasing BMI with augmentation of labour received a higher cumulative oxytocin dose and had a higher maximum oxytocin infusion rate during first stage of labour, however, when adjusted for relevant confounders, the difference was no longer seen. In the future, the guidelines for augmentation of labour with oxytocin infusion might be reconsidered and include modifications related to BMI.
format Online
Article
Text
id pubmed-8006853
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80068532021-04-16 Maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study Ramö Isgren, Anna Kjölhede, Preben Carlhäll, Sara Blomberg, Marie BMJ Open Obstetrics and Gynaecology OBJECTIVE: To evaluate oxytocin use for augmentation of labour in relation to body mass index (BMI) on admission to the labour ward, focusing on cumulative oxytocin dose and maximum rate of oxytocin infusion during the first stage of labour. DESIGN: Prospective observational study. SETTING: Seven hospitals in Sweden. PARTICIPANTS: 1097 nulliparous women with singleton cephalic presentation pregnancy, ≥37 weeks of gestation, spontaneous onset of labour and treatment with oxytocin infusion for labour augmentation. The study population was classified into three BMI subgroups on admission to the labour ward: normal weight (18.5–24.9), overweight (25.0–29.9) and obese (≥30.0). The cumulative oxytocin dose was measured from the start of oxytocin infusion until the neonate was born. PRIMARY OUTCOME: Cumulative oxytocin dose. SECONDARY OUTCOME: Maximum rate of oxytocin infusion during the active phase of first stage of labour. RESULTS: The mean cumulative oxytocin dose increased in the BMI groups (normal weight 2278 mU, overweight 3108 mU and obese 4082 mU (p<0.0001)). However, when adjusted for the confounders (cervical dilatation when oxytocin infusion was started, fetal birth weight, epidural analgesia), the significant difference was no longer seen. The maximum oxytocin infusion rate during the first stage of labour differed significantly in the BMI groups when adjusted for the confounding factors individually but not when adjusted for all three factors simultaneously. In addition, the maximum oxytocin infusion rate was significantly higher in women with emergency caesarean section compared with women with vaginal delivery. CONCLUSIONS: Women with increasing BMI with augmentation of labour received a higher cumulative oxytocin dose and had a higher maximum oxytocin infusion rate during first stage of labour, however, when adjusted for relevant confounders, the difference was no longer seen. In the future, the guidelines for augmentation of labour with oxytocin infusion might be reconsidered and include modifications related to BMI. BMJ Publishing Group 2021-03-25 /pmc/articles/PMC8006853/ /pubmed/33771828 http://dx.doi.org/10.1136/bmjopen-2020-044754 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Obstetrics and Gynaecology
Ramö Isgren, Anna
Kjölhede, Preben
Carlhäll, Sara
Blomberg, Marie
Maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study
title Maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study
title_full Maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study
title_fullStr Maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study
title_full_unstemmed Maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study
title_short Maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study
title_sort maternal body mass index and oxytocin in augmentation of labour in nulliparous women: a prospective observational study
topic Obstetrics and Gynaecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006853/
https://www.ncbi.nlm.nih.gov/pubmed/33771828
http://dx.doi.org/10.1136/bmjopen-2020-044754
work_keys_str_mv AT ramoisgrenanna maternalbodymassindexandoxytocininaugmentationoflabourinnulliparouswomenaprospectiveobservationalstudy
AT kjolhedepreben maternalbodymassindexandoxytocininaugmentationoflabourinnulliparouswomenaprospectiveobservationalstudy
AT carlhallsara maternalbodymassindexandoxytocininaugmentationoflabourinnulliparouswomenaprospectiveobservationalstudy
AT blombergmarie maternalbodymassindexandoxytocininaugmentationoflabourinnulliparouswomenaprospectiveobservationalstudy